Montrusco Bolton Investments Inc. decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 47.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,699 shares of the biopharmaceutical company’s stock after selling 7,070 shares during the period. Montrusco Bolton Investments Inc.’s holdings in Pfizer were worth $271,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently bought and sold shares of PFE. BlackRock Fund Advisors raised its stake in Pfizer by 1.5% in the first quarter. BlackRock Fund Advisors now owns 92,489,121 shares of the biopharmaceutical company’s stock worth $2,741,378,000 after buying an additional 1,403,646 shares during the last quarter. Wellington Management Group LLP raised its stake in Pfizer by 5.0% in the first quarter. Wellington Management Group LLP now owns 82,813,816 shares of the biopharmaceutical company’s stock worth $2,454,601,000 after buying an additional 3,936,078 shares during the last quarter. Franklin Resources Inc. raised its stake in Pfizer by 16.7% in the first quarter. Franklin Resources Inc. now owns 62,902,993 shares of the biopharmaceutical company’s stock worth $1,864,446,000 after buying an additional 9,005,107 shares during the last quarter. BlackRock Group LTD raised its stake in Pfizer by 5.6% in the first quarter. BlackRock Group LTD now owns 59,474,971 shares of the biopharmaceutical company’s stock worth $1,762,838,000 after buying an additional 3,154,116 shares during the last quarter. Finally, Legal & General Group Plc raised its stake in Pfizer by 1.7% in the first quarter. Legal & General Group Plc now owns 29,385,795 shares of the biopharmaceutical company’s stock worth $871,079,000 after buying an additional 488,194 shares during the last quarter. 69.66% of the stock is owned by institutional investors.
Shares of Pfizer Inc. (NYSE:PFE) traded down 0.31% on Friday, hitting $32.66. The company’s stock had a trading volume of 15,569,339 shares. The firm has a market cap of $198.10 billion, a price-to-earnings ratio of 28.95 and a beta of 0.86. The stock has a 50-day moving average price of $34.02 and a 200 day moving average price of $34.27. Pfizer Inc. has a one year low of $28.25 and a one year high of $37.39.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.02. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The business had revenue of $13.10 billion for the quarter, compared to analyst estimates of $13.01 billion. During the same period in the prior year, the company posted $0.56 EPS. The company’s revenue for the quarter was up 10.9% on a year-over-year basis. Equities research analysts predict that Pfizer Inc. will post $2.46 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be paid a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a dividend yield of 3.67%. The ex-dividend date of this dividend is Tuesday, November 8th. Pfizer’s payout ratio is currently 95.24%.
A number of analysts have commented on PFE shares. Vetr raised Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.94 target price for the company in a report on Monday, June 27th. Deutsche Bank AG restated a “buy” rating and issued a $44.00 price target on shares of Pfizer in a research note on Thursday, August 18th. Credit Suisse Group AG restated an “outperform” rating and issued a $40.00 price target on shares of Pfizer in a research note on Monday, August 22nd. Piper Jaffray Cos. set a $54.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, August 23rd. Finally, Jefferies Group set a $41.50 price target on Pfizer and gave the stock a “buy” rating in a research note on Thursday, July 14th. Eleven investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. Pfizer currently has an average rating of “Buy” and a consensus target price of $38.59.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.